KLDO - Kaleido Biosciences picked industry veteran as chief medical officer

Kaleido Biosciences (NASDAQ:KLDO) appointed Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective Dec.15. Dr. Long will be responsible for leading the development of Kaleido’s ongoing and future clinical programs, including the development of KB295 and KB109 in ulcerative colitis and chronic obstructive pulmonary disease, respectively. Dr. Long has almost two decades of experience working in the pharmaceutical and biotechnology industry; most recently she served as interim Chief Medical Officer and SVP, Head of Clinical Development at Freeline Therapeutics.

For further details see:

Kaleido Biosciences picked industry veteran as chief medical officer